Analysts Set Evolus, Inc. (NASDAQ:EOLS) Target Price at $16.00

Evolus, Inc. (NASDAQ:EOLS) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $16.00.

A number of equities research analysts recently commented on EOLS shares. BTIG Research reissued a “buy” rating and issued a $13.00 price target on shares of Evolus in a research report on Wednesday, March 4th. Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Mizuho set a $15.00 price target on shares of Evolus in a research report on Wednesday, February 4th. Stifel Nicolaus cut their price target on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Finally, HC Wainwright decreased their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd.

Insiders Place Their Bets

In other news, insider Rui Avelar sold 29,996 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This trade represents a 6.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 13,669 shares of Evolus stock in a transaction on Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the sale, the insider owned 604,700 shares in the company, valued at $2,872,325. The trade was a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 163,504 shares of company stock worth $797,184 over the last quarter. 5.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Evolus

A number of large investors have recently added to or reduced their stakes in EOLS. Nantahala Capital Management LLC grew its position in shares of Evolus by 1.6% during the 4th quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock valued at $38,707,000 after acquiring an additional 93,792 shares during the period. Caligan Partners LP lifted its stake in Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares during the last quarter. Vanguard Group Inc. grew its holdings in Evolus by 3.3% during the third quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after purchasing an additional 110,693 shares during the period. Braidwell LP bought a new position in Evolus during the fourth quarter valued at $20,650,000. Finally, Soleus Capital Management L.P. increased its position in Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after buying an additional 1,039,842 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Stock Performance

EOLS stock opened at $5.31 on Tuesday. The company has a market capitalization of $345.47 million, a P/E ratio of -6.56 and a beta of 1.00. Evolus has a 52-week low of $3.86 and a 52-week high of $12.28. The business has a 50-day simple moving average of $4.59 and a two-hundred day simple moving average of $5.67.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. As a group, sell-side analysts forecast that Evolus will post -0.43 earnings per share for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.